DNTH (US) share price forecast & AI signal — Dianthus Therapeutics, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in DNTH
Dianthus Therapeutics, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a BUY with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Dianthus Therapeutics, Inc
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $86.03 |
| 2026-11-05 | $83.01 |
| 2026-11-04 | $85.81 |
| 2026-11-03 | $82.70 |
| 2026-11-02 | $82.25 |
| 2026-10-30 | $82.38 |
| 2026-10-29 | $82.70 |
DNTH FAQ
Is Dianthus Therapeutics, Inc (DNTH) a buy or sell this week?
The ACE Stock Bots machine-learning model rates DNTH a BUY for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for DNTH?
Every week the model scores DNTH across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.